&w=384&q=75)
Quality management
Dr Anna Janicka, MD - Director of Quality and Development
%3Aquality(100)&w=3840&q=75)
Since 2014, she has been a member of the Board of Directors of the Polish Society for Reproductive Medicine and Embryology, as well as the Fertility and Infertility Section of the Polish Gynecological Society and the European Society for Human Reproduction and Embryology (ESHRE). Since 2010, she has been directly involved in the implementation of the programs: "European IVF Monitoring (EIM)" for ESHRE and "Oocyte donation study" implemented for the Cross Border Reproductive Care ESHRE - Taskforce. She represented Poland in the Committee of National Representatives of ESHRE in the terms 2014-2017 and 2017-2020.
In 2002 she graduated as the best biotechnology graduate of the Agricultural Academy in Szczecin. She was granted a scholarship by the Minister of National Education and Sport for the academic year 2001/2002. In 2006, she defended her PhD thesis carried out at the Department of Genetics and Pathomorphology of Pomeranian Medical Academy in Szczecin under the supervision of Prof. Jan Lubiński, obtaining the degree of Doctor of Medical Sciences in medical biology (summa cum laude). She was awarded several times by the Minister of Health for a series of publications on molecular biology and diagnosis of hereditary cancer predisposition. After completing her doctoral studies she joined the Department of Genetics and Pathomorphology PUM and ReadGene SA company. In 2007-2010 she worked concurrently as an Assistant in the Department of Medicinal Chemistry at PUM. She has been working at TFP Fertility Vitrolive since 2010, serving as Director of Quality and Development and Coordinator of the Oocyte Donation Program.
Scientific activity
Dr. med. Anna Janicka
Medycyna wspomaganego rozrodu w Polsce – raport za rok 2012 Sekcji Płodności i Niepłodności Polskiego Towarzystwa Ginekologicznego (SPiN PTG) – LINK
Polymorphisms in the oxidative stress-related genes and cancer risk – LINK
Ustawa o leczeniu niepłodności – LINK
Wykorzystanie USG w ocenie stymulacji jajeczkowania – LINK
Assisted reproductive medicine in Poland, 2011-SPiN PTG report – LINK
Polymorphisms in the oxidative stress-related genes and cancer risk – LINK
Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? – LINK
Hereditary breast and ovarian cancer – LINK
DNA testing for variants conferring low or moderate increase in the risk of cancer – LINK
Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology – LINK
Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology – LINK
Breast cancer susceptibility genes – LINK
BARD1 and breast cancer in Poland – LINK
CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors – LINK
Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma – LINK
CDKN2A common variant and multi-organ cancer risk–a population-based study – LINK
Low-risk Genes and Multi-organ Cancer Risk in the Polish Population – LINK
Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer – LINK
The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs – LINK
CHEK2 is a multiorgan cancer susceptibility gene – LINK
&w=3840&q=75)